To Demonstrate Equivalence in Analgesic Efficacy & Bowel Function Between OXN PR Higher Dose & Lower Dose Tablet Strengths in Subjects With Non-cancer or Cancer Pain
PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment
155
Participants
Timeline
Start Date
November 30, 2014
Primary Completion Date
March 31, 2016
Study Completion Date
September 30, 2016
Conditions
Malignant PainNon-malignant Pain
Interventions
DRUG
Oxycodone
DRUG
Naloxone
Prolonged Release Tablets
Trial Locations (1)
Unknown
Mainz
All Listed Sponsors
lead
Mundipharma Research GmbH & Co KG
INDUSTRY
NCT02321397 - To Demonstrate Equivalence in Analgesic Efficacy & Bowel Function Between OXN PR Higher Dose & Lower Dose Tablet Strengths in Subjects With Non-cancer or Cancer Pain | Biotech Hunter | Biotech Hunter